Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid to Prevent Bone Loss in HSCT Recipients
NCT02451462Withdrawn
- Sponsor
- Stanford University
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in osteoporosis comparing Zoledronic acid arm with Placebo arm (2 arms). Primary endpoint: Percent change in Bone Mineral Density at the Femoral Neck at 12 months. Planned start Sep 2015; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02451462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451462.